Early use of immunotherapy in myeloma: TecDara, bispecific consolidation, and alpha emitter therapy

In this discussion, Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone, New York City, NY, Marc Raab, MD, German Cancer Research Center, Heidelberg, Germany, Dickran Kazandjian, MD, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, and Damian Green, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, provide insights into early use of immunotherapy in multiple myeloma (MM). Prof. Raab begins by sharing results with teclistamab plus daratumumab (TecDara) and lenalidomide in high-risk patients receiving frontline transplantation. Following this, Dr Kazandjian and Dr Lin provide updates on the IMMUNOPLANT (NCT06376526) and CARTITUDE-4 (NCT04181827) trials, respectively. Finally, Dr Green highlights the promise of a novel alpha emitter radio-labeled targeted therapy, which may overcome antigen loss when combined with immune checkpoint inhibition. This discussion was filmed at the 19th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео Early use of immunotherapy in myeloma: TecDara, bispecific consolidation, and alpha emitter therapy канала VJHemOnc – Video Journal of Hematology & HemOnc